
Sign up to save your podcasts
Or


This special episode of RealTalk MS is sponsored by Sanofi. By now, you may have come across the term smoldering MS and wondered what it means. An international panel of MS experts has published a consensus statement on the definition, biology, and clinical implications of smoldering MS. Joining me is the lead author of that paper, Dr. Antonio Scalfari.
Dr. Antonio Scalfari has a research background in multiple sclerosis and neuro-inflammatory conditions. From 2003 to 2006, he was a clinical fellow in the neurology department of Oxford University. In 2011, Dr. Scalfari obtained his PhD in neuro-epidemiology at Imperial College London, where he was then a post-doctorate research fellow from 2011 to 2013.
Since 2006, Dr. Scalfari has been working at the London North West Healthcare NHS Trust, and in 2013, he started working at the multiple sclerosis unit at Imperial College Healthcare NHS Trust. In 2017, Dr. Scalfari was appointed as a substantive consultant neurologist. Along with other consultants, he manages the multiple sclerosis and neuro-inflammatory diseases service at Charing Cross and St Mary's hospitals and is a general neurologist at London North West Healthcare NHS Trust.
Sanofi convened the meetings and paid for medical writing assistance, but the authors worked independently to develop and draft the consensus statement. While Dr. Scalfari has been compensated by Sanofi, his views and opinions are his own and do not necessarily reflect those of Sanofi.
By Jon Strum4.7
147147 ratings
This special episode of RealTalk MS is sponsored by Sanofi. By now, you may have come across the term smoldering MS and wondered what it means. An international panel of MS experts has published a consensus statement on the definition, biology, and clinical implications of smoldering MS. Joining me is the lead author of that paper, Dr. Antonio Scalfari.
Dr. Antonio Scalfari has a research background in multiple sclerosis and neuro-inflammatory conditions. From 2003 to 2006, he was a clinical fellow in the neurology department of Oxford University. In 2011, Dr. Scalfari obtained his PhD in neuro-epidemiology at Imperial College London, where he was then a post-doctorate research fellow from 2011 to 2013.
Since 2006, Dr. Scalfari has been working at the London North West Healthcare NHS Trust, and in 2013, he started working at the multiple sclerosis unit at Imperial College Healthcare NHS Trust. In 2017, Dr. Scalfari was appointed as a substantive consultant neurologist. Along with other consultants, he manages the multiple sclerosis and neuro-inflammatory diseases service at Charing Cross and St Mary's hospitals and is a general neurologist at London North West Healthcare NHS Trust.
Sanofi convened the meetings and paid for medical writing assistance, but the authors worked independently to develop and draft the consensus statement. While Dr. Scalfari has been compensated by Sanofi, his views and opinions are his own and do not necessarily reflect those of Sanofi.

38,513 Listeners

12,933 Listeners

69,614 Listeners

15 Listeners

9,247 Listeners

51 Listeners

124 Listeners

8,224 Listeners

41,547 Listeners

117 Listeners

2,153 Listeners

20,306 Listeners

10,764 Listeners

3,705 Listeners

237 Listeners